Best of ASCO® Toronto 2024: Pfizer Breakfast Symposium: Maximizing the potential in ALK+ NSCLC: enhancing outcomes and improving patient care – Dr. Geoffrey Liu & Dr. Brandon Sheffield

Best of ASCO® Toronto 2024: Pfizer Breakfast Symposium: Maximizing the potential in ALK+ NSCLC: enhancing outcomes and improving patient care – Dr. Geoffrey Liu & Dr. Brandon Sheffield

Best of ASCO® Toronto 2024
Icon Chair Speaker

Co-Chairs

Dr. Aly-Khan Lalani
Dr. Natasha Leighl

Icon Chair Speaker

Speakers

Dr. Geoffrey Liu
Dr. Brandon Sheffield

This program has been made possible through unrestricted support from Ipsen

Studies/trials discussed:

  • First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer
  • Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
  • Canadian anaplastic lymphoma kinase study: a model for multicenter standardization and optimization of ALK testing in lung cancer
  • Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer
  • ALTA-1L Study: A Study of Brigatinib Versus Crizotinib in Anaplastic Lymphoma Kinase Positive (ALK+) Advanced Non-small Cell Lung Cancer (NSCLC) Participants (ALTA-1L)
Tagged